Moneycontrol PRO

Sun Pharma: Slowdown in speciality clinical trials needs to be watched

For FY23, we continue with the estimates that the top line of Sun Pharma would grow in a high single digit only

August 03, 2022 / 11:58 AM IST
Sun Pharma: Slowdown in speciality clinical trials needs to be watched

(Representative Image)

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Sun Pharma (CMP: Rs 917; Market Cap: Rs 220,115 crore) has posted a healthy set of numbers, particularly for the US specialty segment. A sequential growth in top line was visible for all the segments. Margins also improved, helped by lower R&D expenses. In the coming quarters, key things to watch are a pick-up in clinical trials, which have been hampered by geopolitical developments, and the competitive intensity in the domestic diabetes market. Specialty products – sequential improvement The sales of specialty...

  • PRO Panorama

    Moneycontrol Pro Panorama | After US, will inflation ease in India?

    Aug 11, 2022 / 03:21 PM IST

    In today’s edition of Moneycontrol Pro Panorama: Nitish Kumar outfoxes BJP in Bihar, the Fed’s tightening may not be working, Nykaa may take on more gloss, and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Shaktikanta Das refuses to pivot 

    Aug 6, 2022 / 10:21 AM IST

    A look at the current macro readings is enough for the RBI governor not to budge and dilute his ‘withdrawal of accommodation’ stance

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers